COMMUNIQUÉS West-GlobeNewswire
-
DaltonTx awarded grant to accelerate AI-powered tuberculosis drug discovery
15/10/2026 -
iOnctura appoints Paul Sekhri as Chair of its Board of Directors
15/10/2026 -
Mission Therapeutics doses first Parkinson’s patient in Phase 1b study of potential disease-modifying treatment MTX325
15/10/2026 -
EXIT-CVD research consortium launches clinical studies to transform cardiovascular care across Europe
15/10/2026 -
invIOs publishes positive clinical data on CBL-B-silenced autologous cell therapy APN401 in peer-reviewed journal
15/10/2026 -
Kuros Biosciences increases 2026 annual guidance, The company reports 40% year-over-year increase in sales in the first nine months of 2026
15/10/2026 -
IBA sélectionnée pour équiper l’expansion aux États-Unis d’un leader de la production de radiopharmaceutiques avec une commande de 12 systèmes Cyclone® KIUBE
15/10/2026 -
IBA selected to support the US expansion of a leading radiopharmaceutical producer with an order for 12 Cyclone® KIUBE systems
15/10/2026 -
argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026
15/10/2026 -
OSE Immunotherapeutics présentera lors de la 10ème Chardan Annual Healthcare Conference
15/10/2026 -
OSE Immunotherapeutics to Present at Chardan’s 10th Annual Healthcare Conference
15/10/2026 -
OMass Therapeutics Announces $310 Million Series C Financing to Advance Portfolio of Small Molecule Therapeutics in Endocrinology and Immunology
15/10/2026 -
Interpace Biosciences Announces Preliminary Unaudited Third Quarter 2026 Revenue
15/10/2026 -
EC-Council Releases ADG 2.0 and Offers Its AI Governance Crosswalks Free to Every Government, Regulator and Standards Body as Nations Split on AI Rules
15/10/2026 -
Golden Touch Fusion CBD Gummies: Official Product Information for Adults as the Federal Hemp Definition Changes November 12, 2026
14/10/2026 -
EmblemHealth Maintains 4-Star Medicare Rating, Highlighting Sustained Quality Performance
14/10/2026 -
Belite Bio Announces Multi-Market Submission of Marketing Authorization Applications Via the Access Consortium Pathway for Tinlarebant for the Treatment of Stargardt Disease Type 1
14/10/2026 -
Lakefront Announces Sale of Preclinical CAR-T Programs to Armed Cell Therapeutics
14/10/2026 -
MannKind to Participate in the Chardan Healthcare Conference
14/10/2026
Pages